- Poster presentation
- Open Access
Long-term follow-up of systemic onset juvenile idiopathic arthritis patients treated with Anakinra
© Gattorno et al; licensee BioMed Central Ltd. 2011
- Published: 14 September 2011
- Juvenile Idiopathic Arthritis
- Juvenile Idiopathic Arthritis Patient
- Partial Responder
Anakinra is effective in a subgroup of SoJIA patients
To analyze the long-term follow-up of Anakinra-treated patients
34 SoJIA patients (19 M, 15 F) were treated with Anakinra at the staring dose of 1 mg/kg/die. Complete response: no clinical and laboratory activity in absence of other treatments; partial response: active disease despite anakinra; no responders: withdraw of Anakinra due to inefficacy.
The mean follow-up was 4.02 year (range 1.05 - 6.16). At the last follow-up 13 patients were complete responders, 5 partial responders and 16 non responder.
Among complete responders, 4 patients withdrawn Anakinra without relapses after a mean of 3 years of treatment, 7 are in remission using anakinra only, 2 patients were switched to anti IL-1 monoclonal antibody with a full response. Despite the good control of their disease 11/13 displayed at least one relapse of their disease during the follow-up with a total of 22 relapses (range 1-4 for patient).
Among partial responders two patients were previously considered as complete responders. In 16 non responders patients subsequent treatments were canakinumab (1 pt), tocilizumab (5 patients), or combined immunosuppressive treatment and/or anti-TNF (10 pts). Two non-responders patients died. Responders patients confimed to have an higher number of active joints at baseline (p = 0.006) and higher WBC and neutrhophils count (p = 0.002). Newly enrolled responder patients has a significantly shorter disease duration in respect to non responder patients (p = 0.03).
Anakinra response still dissect two distinct populations of SoJIa patients
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.